Surface-modified antiasthmatic dry powder aerosols inhaled intratracheally reduce the pharmacologically effective dose

Pharmaceutical Research

Volumn 15, Issue 11, 1998, Pages 1753-1759

  Kawashima, Yoshiaki ^a   Serigano, Takanori ^a   Hino, Tomoaki ^a,b   Yamamoto, Hiromitsu ^a   Takeuchi, Hirofumi ^a  

^a GIFU PHARMACEUTICAL UNIVERSITY   (Japan)

^b UNIVERSITY OF TOKUSHIMA   (Japan)

Author keywords

Aerosol therapy; Dry powder inhalation; Intratracheal administration; Leukotriene D4; Leukotriene inhibitor; Pranlukast hydrate

Indexed keywords

ANTIASTHMATIC AGENT; CARBOXYMETHYLCELLULOSE; HYDROXYPROPYLMETHYLCELLULOSE PHTHALATE; LEUKOTRIENE D4; POLYSORBATE 80; TROMETAMOL;

AEROSOL; ANIMAL EXPERIMENT; ARTICLE; ASTHMA; BRONCHOSPASM; CHEMICAL MODIFICATION; CONTROLLED STUDY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; DRUG TISSUE LEVEL; DRY POWDER; GUINEA PIG; HYDROPHILICITY; INHALATIONAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; LUNG LOBE; NONHUMAN; ORAL DRUG ADMINISTRATION; PARTICLE SIZE; POWDER INHALER; PRIORITY JOURNAL; TOPICAL DRUG ADMINISTRATION;

ADMINISTRATION, INHALATION; AEROSOLS; ANIMALS; ANTI-ASTHMATIC AGENTS; BRONCHOCONSTRICTOR AGENTS; CHROMONES; DOSE-RESPONSE RELATIONSHIP, DRUG; GUINEA PIGS; INTUBATION, INTRATRACHEAL; LEUKOTRIENE ANTAGONISTS; LEUKOTRIENE D4; LINEAR MODELS; POWDERS; REPRODUCIBILITY OF RESULTS; SURFACE PROPERTIES;

EID: 0031756191     PISSN: 07248741     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1011968914726     Document Type: Article

References (13)

1. S. J. Smith and J. A. Bernstein, Therapeutic uses of lung aerosols. In A. J. Hickey (eds.), Inhalation Aerosols, Marcel Dekker, New York, 1996, pp. 233-269.
2. P. Gupta, Y. Qiu, and A. Adjei. Pulmonary delivery of the 5-lipoxtgenase inhibitor, Abbott-85761, in beagle dogs. Int. J. Pharm. 147:207-218 (1997).
3. T. Serigano, T. Hino, H. Yamamoto, H. Takeuchi, and Y. Kawashima. The design of inhalation dry powders by the surface modification of drug particles. J. Soc. Powder Technol., Japan, 33:559-563 (1996).
4. N. Nakagawa, T. Obata, T. Kobayashi, Y. Okada, F. Nambu, T. Terawaki, and H. Aishita. In vivo pharmacologie profile of ONO-1078: A potent, selective and orally active peptide leukotriene (LT) antagonist. Japan. J. Pharmacol. 60:217-225 (1992).
5. Y. Taniguchi, G. Tamura, M. Honma, T. Aizawa, N. Maruyama, K. Shirato, and T. Takishima. The effect of an oral leukotoriene antagonist, ONO-1078, on allergen-induced immediate broncho-constriction in asthmatic subjects. J. Allergy Clin. Immunol. 92:507-512 (1993).
6. Y. Kawashima, T. Niwa, T. Handa, H. Takeuchi, T. Iwamoto, and Y. Ito. Preparation of controlled-release microspheres of ibuprofen with acrylic polymers by a novel quasi-emulsion solvent diffusion method. J. Pharm. Sci. 78:68-72 (1989).
7. T. Niwa, H. Takeuchi, T. Hino, N. Kunou, and Y. Kawashima. Preparation of biodegradable nanospheres of water soluble and insoluble drugs with DL-lactide/glycolide copolymer, and the drug release behavior. J. Contr. Rel. 25:89-98 (1993).
8. H. Konzett and R. Ressler. Versuchsanordnung zu Untersuchungen an der bronchialmuskulatur. Arch. Exp. Pathol. Pharmakol. 195:71-74 (1940).
9. P. K. Gupta and A. J. Hickey. Contemporary approaches in aerosolized drug delivery to the lung. J. Contr. Rel. 17:127-147 (1991).
10. M. P. Timsina, G. P. Martin, C. Marriott, D. Ganderton, and M. Yianneskis. Drug delivery to the respiratory tract using dry powder inhalers. Int. J. Pharm. 101:1-13 (1994).
11. K. Okumura, S. Iwakawa, T. Yoshida, T. Seki and F. Komada. Intratracheal delivery of insulin -Absorption from solution and aerosol by rat lung. Int. J. Pharm. 88:63-73 (1992).
12. R. W. Niven, F. D. Lott, A. Y. Ip, and J. M. Cribbs. Pulmonary delivery of powders and solutions containing recombinant human granulocyte colony-stimulating factor (rhG-CSF) to the rabbit. Pharm. Res. 11:1101-1109 (1994).
13. A. M. Taburet and B. Schmit. Pharmacokinetic optimisation of asthma treatment. Clin. Pharmacokinet. 26:396-418 (1994).